Risk Factors for Predictors of MACEs After RA-CABG

Overview

As the secondary choice of artery grafts, radial artery is more and more used to achieve multiple arterial revascularization in CABG. Risk factors for predictors of major cardiovascular adverse events (MACE) after CABG using radial-artery grafts (RA-CABG), however, remain uncertain. This case-control study aims to identify the baseline predictors of MACE after RA-CABG. We will collect the baseline characteristics and perioperative data of patients underwent RA-CABG from Jan. 2009 to Dec. 2019 in our single center. By reviewing the latest follow-up records, we will examine the correlation between the baseline characteristics and clinical outcomes (MACEs), then identify the independent risk factors for predictors of MACEs after RA-CABG.

Full Title of Study: “Risk Factors for Predictors of Major Adverse Cardiovascular Events After Coronary Artery Bypass Using Radial Artery Grafts”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Retrospective
  • Study Primary Completion Date: November 30, 2021

Arms, Groups and Cohorts

  • MACE Group
    • MACE Group includes the patients suffered from any component of MACE after RA-CABG until the latest follow-up.
  • Non-MACE Group
    • Non-MACE Group includes the patients freed from any component of MACE after RA-CABG until the latest follow-up.

Clinical Trial Outcome Measures

Primary Measures

  • 7-day MACE-4
    • Time Frame: 7 days post-CABG
    • a composite of all-cause death, myocardial infraction, stroke and repeat revascularization
  • 30-day MACE-4
    • Time Frame: 30 days post-CABG
    • a composite of all-cause death, myocardial infraction, stroke and repeat revascularization
  • 1-year MACE-4
    • Time Frame: 1 year post-CABG
    • a composite of all-cause death, myocardial infraction, stroke and repeat revascularization
  • 3-year MACE-4
    • Time Frame: 3 years post-CABG
    • a composite of all-cause death, myocardial infraction, stroke and repeat revascularization

Secondary Measures

  • MACE-3
    • Time Frame: 7 days, 30 days, 1 year, and 3 years post-CABG
    • a composite of CV-death, myocardial infraction and stroke
  • All-cause death
    • Time Frame: 7 days, 30 days, 1 year, and 3 years post-CABG
    • Death from any cause
  • CV-death
    • Time Frame: 7 days, 30 days, 1 year, and 3 years post-CABG
    • Including death resulting from an acute myocardial infarction , sudden cardiac death, death due to heart failure, death due to stroke, death due to cardiovascular procedures, death due to cardiovascular hemorrhage, and death due to other cardiovascular causes
  • Myocardial infraction
    • Time Frame: 7 days, 30 days, 1 year, and 3 years post-CABG
    • According to the 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials, including CABG-related MI, non CABG-related MI, silent MI and unknown type.
  • Stroke
    • Time Frame: 7 days, 30 days, 1 year, and 3 years post-CABG
    • According to the 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials, including ischemic, hemorrhagic and unknown type.
  • Repeat revascularization
    • Time Frame: 7 days, 30 days, 1 year, and 3 years post-CABG
    • According to the 2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials, including any PCI and CABG.

Participating in This Clinical Trial

Inclusion Criteria

  • Underwent CABG using at least a radial artery grafts from Jan.2009 to Dec.2019. with or without cardiopulmonary bypass , with or without concomitant procedure – Aged 18 and above at procedure – With any gender Exclusion Criteria:

  • With unavailable medical records

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Ruijin Hospital
  • Provider of Information About this Clinical Study
    • Principal Investigator: Qiang Zhao,MD, Professor and Director, Department of Cardiovascular Surgery, Vice President, Ruijin Hospital – Ruijin Hospital
  • Overall Official(s)
    • Qiang Zhao, MD, Principal Investigator, Ruijin Hospital
    • Yunpeng Zhu, MD, Principal Investigator, Ruijin Hospital

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.